Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb names new CEO

Lamberto Andreotti will take over from James Cornelius as CEO at Bristol-Myers Squibb, with Cornelius staying on as chairman  

Bristol-Myers Squibb (BMS) has announced that Lamberto Andreotti, 59, will become the company's chief executive officer on May 4, when James M Cornelius, 66, current chairman and CEO, retires. At the request of the board, Cornelius will remain as chairman. 

"Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey," said Lamberto Andreotti, who is currently president, chief operating officer and a member of the board.  

Lamberto has the full support of Cornelius, who said: "Lamberto has demonstrated extraordinary leadership as president and chief operating officer and I believe he is the natural candidate to replace me as CEO. I have a high level of confidence in Lamberto and that is shared by everyone who has seen him consistently and successfully drive performance."  

Andreotti has been president and chief operating officer since March 2009, responsible for the global pharmaceutical business. He has been with BMS for 12 years in senior international roles. Prior to this he held senior roles at KABI Pharmacia and Pharmacia & Upjohn. 

3rd March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...